Consistent with this, within the recently published Project DRIVE (McDonald et al., 2017) database we observe, that among the almost 400 cancer cell lines assayed, synovial sarcoma cell lines are the most sensitive to BRD9 targeting (Figure 1E). Here, BRD9 is linked to cancer.